Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
- Author
- CHOI, Brian S1 ; SONDEL, Paul M2 3 4 ; ALBERTINI, Mark R8 ; HANK, Jacquelyn A2 ; SCHALCH, Heidi1 ; GAN, Jacek2 ; KING, David M1 ; KENDRA, Kari5 ; MAHVI, David6 ; LEE, Li-Yin7 ; KIM, Kyungmann7
[1] Department of Medicine, University of Wisconsin, Madison, WI, United States
[2] Department of Human Oncology, University of Wisconsin, Madison, WI, United States
[3] Department of Pediatrics, University of Wisconsin, Madison, WI, United States
[4] Department of Genetics, University of Wisconsin, Madison, WI, United States
[5] Department of Hematology and Oncology, Ohio State University, Columbus, OH, United States
[6] Department of Surgery, University of Wisconsin, Madison, WI, United States
[7] Department of Biostatistics, University of Wisconsin, Madison, WI, United States
[8] K4/414 Clinical Science Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, United States - Source
Cancer immunology and immunotherapy. 2006, Vol 55, Num 7, pp 761-774, 14 p ; ref : 38 ref
- CODEN
- CIIMDN
- ISSN
- 0340-7004
- Scientific domain
- Biochemistry, molecular biology, biophysics; Medical oncology; Immunology, immunopathology, allergology
- Publisher
- Springer, Berlin
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Antibody-dependent cell cytotoxicity Ganglioside GD2 Ganglioside GD3 Immunotherapy Melanoma
- Keyword (fr)
- Anticorps monoclonal Essai clinique phase I Ganglioside Homme Immunothérapie Interleukine 2 Mélanome malin Réaction ADCC Sarcome Traitement associé Cytokine Tumeur maligne
- Keyword (en)
- Monoclonal antibody Phase I trial Ganglioside Human Immunotherapy Interleukin 2 Malignant melanoma Antibody-dependent cell cytotoxicity Sarcoma Combined treatment Cytokine Malignant tumor
- Keyword (es)
- Anticuerpo monoclonal Ensayo clínico fase I Gangliósido Hombre Inmunoterapia Interleuquina 2 Melanoma maligno Reacción ADCC Sarcoma Tratamiento asociado Citoquina Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R03 Immunotherapy
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B08 Dermatology / 002B08A Tumors of the skin and soft tissue. Premalignant lesions
- Discipline
- Dermatology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17704641
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00262-005-0069-7 
https://dx.doi.org/10.1007/s00262-005-0069-7
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00262-005-0069-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Cancer immunology and immunotherapy\";s:9:\"\u0000*\u0000stitle\";s:26:\"Cancer immunol. immunother\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"55\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"761\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0340-7004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHOI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Brian S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"SONDEL, Paul M\";i:1;s:17:\"ALBERTINI, Mark R\";i:2;s:17:\"HANK, Jacquelyn A\";i:3;s:14:\"SCHALCH, Heidi\";i:4;s:10:\"GAN, Jacek\";i:5;s:13:\"KING, David M\";i:6;s:12:\"KENDRA, Kari\";i:7;s:12:\"MAHVI, David\";i:8;s:11:\"LEE, Li-Yin\";i:9;s:14:\"KIM, Kyungmann\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIIMDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00262-005-0069-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Cancer immunology and immunotherapy\";s:9:\"\u0000*\u0000stitle\";s:26:\"Cancer immunol. immunother\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"55\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"761\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0340-7004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHOI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Brian S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"SONDEL, Paul M\";i:1;s:17:\"ALBERTINI, Mark R\";i:2;s:17:\"HANK, Jacquelyn A\";i:3;s:14:\"SCHALCH, Heidi\";i:4;s:10:\"GAN, Jacek\";i:5;s:13:\"KING, David M\";i:6;s:12:\"KENDRA, Kari\";i:7;s:12:\"MAHVI, David\";i:8;s:11:\"LEE, Li-Yin\";i:9;s:14:\"KIM, Kyungmann\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIIMDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00262-005-0069-7\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00262-005-0069-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Cancer immunology and immunotherapy\";s:9:\"\u0000*\u0000stitle\";s:26:\"Cancer immunol. immunother\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"55\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"761\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0340-7004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHOI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Brian S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"SONDEL, Paul M\";i:1;s:17:\"ALBERTINI, Mark R\";i:2;s:17:\"HANK, Jacquelyn A\";i:3;s:14:\"SCHALCH, Heidi\";i:4;s:10:\"GAN, Jacek\";i:5;s:13:\"KING, David M\";i:6;s:12:\"KENDRA, Kari\";i:7;s:12:\"MAHVI, David\";i:8;s:11:\"LEE, Li-Yin\";i:9;s:14:\"KIM, Kyungmann\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIIMDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00262-005-0069-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Cancer immunology and immunotherapy\";s:9:\"\u0000*\u0000stitle\";s:26:\"Cancer immunol. immunother\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"55\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"761\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0340-7004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHOI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Brian S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"SONDEL, Paul M\";i:1;s:17:\"ALBERTINI, Mark R\";i:2;s:17:\"HANK, Jacquelyn A\";i:3;s:14:\"SCHALCH, Heidi\";i:4;s:10:\"GAN, Jacek\";i:5;s:13:\"KING, David M\";i:6;s:12:\"KENDRA, Kari\";i:7;s:12:\"MAHVI, David\";i:8;s:11:\"LEE, Li-Yin\";i:9;s:14:\"KIM, Kyungmann\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIIMDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00262-005-0069-7\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Cancer immunology and immunotherapy\";s:9:\"\u0000*\u0000stitle\";s:26:\"Cancer immunol. immunother\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"55\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:3:\"761\";s:8:\"\u0000*\u0000epage\";s:3:\"774\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0340-7004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"CHOI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Brian S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:14:\"SONDEL, Paul M\";i:1;s:17:\"ALBERTINI, Mark R\";i:2;s:17:\"HANK, Jacquelyn A\";i:3;s:14:\"SCHALCH, Heidi\";i:4;s:10:\"GAN, Jacek\";i:5;s:13:\"KING, David M\";i:6;s:12:\"KENDRA, Kari\";i:7;s:12:\"MAHVI, David\";i:8;s:11:\"LEE, Li-Yin\";i:9;s:14:\"KIM, Kyungmann\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIIMDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:134:\"Phase I trial of combined treatment with chl4.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
